Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis
- PMID: 34922421
- PMCID: PMC8920735
- DOI: 10.4178/epih.e2021103
Effects of early medication treatment and metformin use for cancer prevention in diabetes patients: a nationwide sample cohort study in Korea using extended landmark time analysis
Abstract
Objectives: This study investigated the effectiveness of early medication treatment and metformin use for cancer prevention in type 2 diabetes patients.
Methods: Population-based cohort data were used from the Korean National Health Insurance Service-National Sample Cohort database (KNHIS-NSC) for 2002-2013. Patient-specific medication prescription status was defined by the landmark time (LMT; a fixed time after cohort entry), considering both pre- and post-LMT prescriptions to control methodological biases in observational research. The LMT was set to 2 years. Logistic regression analysis with multivariable adjustment was conducted to analyze cancer incidence by patient-specific medication prescription status.
Results: Only 33.4% of the subjects were prescribed medication early (before the LMT) with compliance. Cancer incidence in individuals with early prescription and compliance was 25% lower (odds ratio [OR], 0.75; 95% confidence interval [CI], 0.67 to 0.84) than in those without. As early-prescribed medications, metformin monotherapy and metformin combination therapy were associated with 34% (OR, 0.66; 95% CI, 0.51 to 0.83) and 25% (OR, 0.75; 95% CI, 0.64 to 0.88) lower cancer risk than non-use, respectively. Patients who were prescribed late (post-LMT) but did not comply with the prescription had a 24% (OR, 1.24; 95% CI, 0.97 to 1.58) higher cancer incidence than non-users. Among patients who started monotherapy early without changes throughout the entire follow-up period, those who started on metformin had a 37% (OR, 0.63; 95% CI, 0.41 to 0.99) lower risk of cancer than non-metformin users.
Conclusions: Doctors must prescribe antidiabetic medication early, and patient compliance is required, regardless of the prescription time, to prevent cancer. Metformin monotherapy or combination therapy is recommended as an early prescription.
Keywords: Anticancer agents; Drug prescription; Medication compliance; Metformin; Type 2 diabetes mellitus.
Conflict of interest statement
The authors have no conflicts of interest to declare for this study.
Figures


Similar articles
-
Prescription trends and the selection of initial oral antidiabetic agents for patients with newly diagnosed type 2 diabetes: a nationwide study.Public Health. 2017 Nov;152:20-27. doi: 10.1016/j.puhe.2017.06.008. Epub 2017 Jul 15. Public Health. 2017. PMID: 28719837
-
Metformin Use and the Risk of Cancer in Patients with Diabetes: A Nationwide Sample Cohort Study.Cancer Prev Res (Phila). 2020 Feb;13(2):195-202. doi: 10.1158/1940-6207.CAPR-19-0427. Epub 2019 Nov 7. Cancer Prev Res (Phila). 2020. PMID: 31699707
-
First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs.Diabet Med. 2021 Sep;38(9):e14622. doi: 10.1111/dme.14622. Epub 2021 Jun 29. Diabet Med. 2021. PMID: 34133781
-
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.Pharmacoeconomics. 2004;22(6):389-411. doi: 10.2165/00019053-200422060-00005. Pharmacoeconomics. 2004. PMID: 15099124 Review.
-
Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.BMC Infect Dis. 2019 Oct 17;19(1):859. doi: 10.1186/s12879-019-4548-4. BMC Infect Dis. 2019. PMID: 31623569 Free PMC article.
Cited by
-
Combination of Metformin and Sorafenib Induces Ferroptosis of Hepatocellular Carcinoma Through p62-Keap1-Nrf2 Pathway.J Cancer. 2022 Sep 6;13(11):3234-3243. doi: 10.7150/jca.76618. eCollection 2022. J Cancer. 2022. PMID: 36118519 Free PMC article.
-
Long-Term Use of Metformin and Vitamin B12 Deficiency in Diabetes.Curr Drug Saf. 2025;20(3):258-270. doi: 10.2174/0115748863308106240816044733. Curr Drug Saf. 2025. PMID: 39206482 Review.
-
Association between metformin use and the risk of developing open-angle glaucoma among patients with diabetes: a retrospective cohort study and meta-analysis.Int Ophthalmol. 2024 Feb 5;44(1):6. doi: 10.1007/s10792-024-02945-w. Int Ophthalmol. 2024. PMID: 38316664
References
-
- Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. - PubMed
-
- Kim HJ, Jee SH. Insulin resistance and cancer. Korean J Epidemiol. 2005;27:38–50. (Korean).
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials